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Thrombocytopenia in critically ill surgical patients:
a case–control study evaluating attributable mortality and
transfusion requirements
François Stephan, Jacques de Montblanc, Ali Cheffi and Francis Bonnet
Background: That thrombocytopenia results in increased mortality or
transfusion requirements has not been confirmed by previous studies. We
performed a case–control study in which 36 patients who developed severe
thrombocytopenia of less than 50×109 platelets/l were carefully matched for the
severity of underlying disease and other important variables.
Results: Seventeen (47%) thrombocytopenic patients died, versus 10 (28%)
matched control patients who were not thrombocytopenic. Nine pairs had a
discordant outcome, and in eight of these pairs the thrombocytopenic patient
died (exact binomial probability 0.037). The estimated attributable mortality was
19.5% (95% confidence interval 3.2–35.8), and the estimated odds ratio was
2.7 (95% confidence interval 1.02–7.10). Thrombocytopenic patients had
comparable values for severity of illness scores between day of admission and
day of thrombocytopenia, in contrast with control patients who had a statistically
significant decrease in severity of illness scores during the same period. Thirty
(83%) of the thrombocytopenic patients required transfusion of blood products,
versus 21 (58%) control patients (paired c2 test 4.92, P<0.04). The estimated
attributable transfusion requirement was 25% (95% confidence interval
5.4–44.6), and the estimated odds ratio was 1.52 (95 confidence interval
1.05–2.20).
Conclusion: The present study suggests that thrombocytopenia of less than
50×10 9 platelets/l may be a marker for more severe illness and increased risk of
death, rather than causative, because a true causal relationship is not
established. Thrombocytopenia also leads to an excess of blood product
consumption.
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Introduction
Thrombocytopenia is a well known complication in inten-
sive care unit (ICU) patients. It has been associated with
various risk factors, but mainly with sepsis [1–3]. The inci-
dence of thrombocytopenia of less than 100×109 platelets/l
in ICU patients has been reported to vary from 23 to 41%,
but lower frequencies (10–17%) have been reported for
counts lower than 50×109 platelets/l [1–3]. Mortality rates
as high as 38–54% have been observed, and have been
reported to be proportional to the nadir of the platelet
count [1,3,4]. Previous studies have not clearly
demonstrated that thrombocytopenia results in increased
mortality or increased transfusion requirements, however.
Two independent factors have made this important and
seemingly straightforward issue difficult to resolve.
First, mortality rates are high in such patients for many
reasons. Numerous studies [1,3,5–7] have demonstrated
that severe underlying illness predisposes to the develop-
ment of thrombocytopenia in ICU patients, and the influ-
ence of thrombocytopenia on mortality is therefore diffi-
cult to assess. Although thrombocytopenia in the critically
ill is more often a symptom than a disease process per se, it
might increase mortality in several ways. Thrombo-
cytopenia can result in a mild, moderate, or severe haemor-
rhagic disorder, which could enhance the risk of morbidity
and mortality in critically ill surgical patients [8]. The
adverse effects of anaemia in such patients have also
recently been discussed [9,10]. Apart from its haemostatic
effect, thrombocytopenia also increases the susceptibility
to and severity of certain infections [11]. Although several
studies have found a relationship between thrombocyto-
penia and the likelihood of death, especially in septic
patients [1,3,4,7,12], thrombocytopenia has rarely been
identified as an independent predictive factor of death
using multiple logistic regression [5,6,13]. Nevertheless,
these previous studies failed to reach any definite conclu-
sions regarding whether thrombocytopenia per se was
ICU = intensive care unit; APACHE = Acute Physiology and Chronic Health Evaluation; CI = confidence interval; DIC = disseminated intravascular
coagulation; ODIN = organ dysfunstion and/or infection; RBC = red blood cell; SAPS = Simplified Acute Physiology Score.responsible for the poorer prognosis, or whether this higher
mortality simply reflected more severe underlying illness.
Second, the threshold value for severe thrombocytopenia
that is supposed to jeopardize the prognosis is difficult to
determine. We and others [1,3,13] have suggested that a
platelet count less than 50×109/l is associated with a poor
outcome. Moreover, guidelines for platelet transfusion [8]
have proposed that the threshold value of 50×109
platelets/l is indicative of platelet transfusion requirement
in surgical patients.
One of the commonest methods to evaluate excess mortal-
ity is to perform a case–control study in which confound-
ing variables (eg severity of underlying illness, reason for
hospitalization, and so forth) are carefully matched in the
two populations. To date, however, no case–control
studies that have evaluated morbidity and mortality asso-
ciated with thrombocytopenia in ICU patients have been
published in which these important variables have been
carefully matched.
We therefore designed a case–control study to determine
to what extent severe thrombocytopenia (defined as
<50×109 platelets/l) increases mortality and blood product
requirements in surgical ICU patients.
Methods
Study design
We performed a matched cohort study, with a matched
control patient without thrombocytopenia for each
thrombocytopenic patient (1:1 matching). The study was
conducted in the Service de Réanimation Chirurgicale of
Tenon University Hospital in Paris. This 8-bed ICU
admits patients from all surgical departments and operat-
ing rooms of the hospital. The study period ran from
January 1, 1996 to December 31, 1996, during which time
298 patients were admitted to the ICU and thrombo-
cytopenic patients were prospectively identified.
Case identification
Platelet count was performed daily for all patients.
Patients who experienced even a single episode of
thrombocytopenia of less than 50×109 platelets/l during
the ICU stay were classified as ‘cases’. Low platelet
counts were confirmed by direct examination of the blood
smear. Platelet transfusions were administered to actively
bleeding patients and patients scheduled for emergency
surgery if their platelet count fell below 50×109/l.
Likewise, platelet transfusions were administered to
patients at risk for bleeding complications (eg postopera-
tive patients, or after gastrointestinal bleeding) when their
platelet count fell below 20×109/l [8,14].
None of patients with a history of platelet disorders,
haematologic malignancies or chemotherapy, splenec-
tomy, mechanical heart valves, or patients undergoing
cardiopulmonary bypass surgery were included in the
patient population.
Matching and selection of control patients
Control patients had to have had no evidence of severe
thrombocytopenia (<50×109 platelets/l) at any time
during hospitalization in the ICU. A computer-generated
list of eligible control patients was obtained from a data-
base that included 695 patients hospitalized between
November, 1995 and March, 1998. Control patients were
selected according to the following matching criteria: age
(±5 years), Acute Physiology and Chronic Health Evalua-
tion (APACHE) II score calculated on the first day of ICU
admission (±5 points), primary diagnosis and duration of
stay in the ICU (±5 days). The list of potential control
patients was reviewed for the best possible match, giving
highest priority to primary diagnosis, duration of stay in
the ICU, APACHE II score and age. In the case of multi-
ple acceptable control patients, the one with the date of
ICU admission closest to that of the patient was chosen.
Collection of data
The following information was recorded: primary diagno-
sis; age; sex; dates of admission and discharge from the
ICU; previous health status; severity of underlying
medical conditions stratified according to the criteria of
McCabe and Jackson [15] as fatal, ultimately fatal and
nonfatal; first-day organ dysfunction and/or infection
(ODIN) score [16], based on the presence or absence of
cardiac, respiratory, renal, hepatic, neurologic, haemato-
logic dysfunctions and/or infection; red blood cells
(RBCs); fresh frozen plasma and platelet transfusion
requirements; and full blood count and coagulation
studies (factor V assay and D-dimer detection were per-
formed only when prothrombin time was abnormal). The
severity of illness was evaluated with the first-day
APACHE II score [17] and the first-day new Simplified
Acute Physiology Score (SAPS) II [18].
The criteria of sepsis have previously been reported [19].
Shock was defined as a decrease in systolic blood pressure
(<90mmHg) despite adequate vascular filling or the need
for vasoactive drugs (dopamine >5mg/kg per min, dobuta-
mine, epinephrine, or norepinephrine).
The definition of disseminated intravascular coagulation
(DIC) required the following four criteria: a platelet count
less than 150×109/l; a decrease in prothrombin level
activity to less than 50%; a decrease in the level of factor V
to less than 50%; and the presence of fibrin degradation
products (D-dimers).
Statistical analysis
Analysis of prior data from our unit indicated that the odds
ratio for death was 3.9 for cases and that the mortality rate
152 Critical Care 1999, Vol 3 No 6for control patients was 23% [3]. On the basis of these
results, we estimated that 28 patients in each group (control
and case) would be required to test the null hypothesis at
the 0.05 significance level with a power of 0.7 [20].
The attributable mortality due to severe thrombocyto-
penia was defined as the crude mortality rate of the
control patients subtracted from that of the cases. The
point estimate of the attributable mortality and 95% confi-
dence intervals (CIs) were calculated as previously
described [21]. McNemar’s test with continuity correction
and exact binomial probabilities were used to determine
whether the crude mortality rates of the cases and control
patients were significantly different [21]. Because the
study involved a matched cohort, the odds ratio was used
as a measure of relative risk. Because incidence of
outcome is more than 10%, correction of the odds ratio
was made according to the method of Zhang and Yu [22]
in order to represent better the true relative risk. The 95%
CI of the odds ratio was calculated using Miettinen’s test-
based approach [21].
Differences in medians were tested using Wilcoxon’s test
for continuous variables and the c2 test for categorical vari-
ables, with Yates’ correction when appropriate. Quantita-
tive data were expressed as means±standard deviation.
P<0.05 was considered statistically significant.
Results
Study population
During the study period, 36 of the 298 studied ICU
patients developed severe thrombocytopenia of less than
50×109 platelets/l, producing a global incidence rate of 12
episodes of thrombocytopenia per 100 admissions.
Thrombocytopenia occurred 3.2±4.8 days (median 2 days,
interquartile range 2.5 days, range 0–26 days) after ICU
admission, for a mean duration of 3.4±2.9 days (median 2
days, interquartile range 4 days, range 1–13 days). Throm-
bocytopenia was related to sepsis in eight patients; sepsis
and DIC in 11 patients; bleeding in nine patients; bleed-
ing and DIC in six patients; undetermined shock and DIC
in one patient; and haemolysis–elevated liver enzymes–
low platelets syndrome with DIC in one patient. Matching
was performed for these 36 patients.
On admission to ICU, the mean platelet count was
127±75×109/l (median 116) versus 199±123×109/l (median
161) in cases and control patients, respectively (not
significant). During ICU stay, mean nadir platelet count was
28±14×109/l (median 29.5) versus 184±142×109/l (median
114); mean nadir haemoglobin value was 6.9±1.7g/dl
(median 7.2) versus 8.7±2.3g/dl (median 8; P=0.009); and
mean nadir leucocyte count was 6.2±4.1×109/l versus
10.2±4.9×109/l (P<0.0004) in cases and control patients,
respectively. Nineteen cases (52.7%) and eight control
patients (22.2%) had evidence of DIC (P<0.01).
Closeness of matching
The median age of the cases was 65 years (range 27–104
years, mean 60.7 years) versus 65 years (range 27–83 years,
mean 60.6 years) for control patients. Twenty-one (58%)
case–control pairs differed by no more than 3 years, and 27
(75%) by no more than 5 years (Table 1). The median
APACHE II score of cases was 21 (range 5–41, mean 20.8)
versus 21 for control patients (range 4–37, mean 22.7).
The median duration of ICU stay of cases was 5 days
(range 1–35 days, mean 8.3 days) versus 4 days for control
patients (range 1–26 days, mean 6.4 days). Thirty-five
(97%) of the pairs were matched for primary diagnosis.
Overall, matching was successful for 243 out of 288
(84.3%) variables.
Because the study end point — mortality — is strongly
related to severity of illness and/or initial respiratory
status [17,18], we controlled matching by comparing
another seven criteria that evaluated the severity of
disease in the two groups of patients (Table 2). No signif-
icant differences in these indices were observed between
cases and control patients. This was particularly the case
when comparing the four variables that were individually
predictive of survival for all patients: mean SAPS II score,
mean number of organ-system failures, number of
patients with cardiac failure on admission, and number of
patients with renal failure on admission. The sex ratio of
the two groups was also similar. Finally, the dates of
admission of cases and control patients differed by less
than 1 year in 27 pairs (75%).
Mortality
Seventeen (47%) cases died, versus 10 (28%) control
patients (Table 3). Twenty-seven matched pairs had a
concordant outcome (18 lived and nine died). Nine pairs
had a discordant outcome, and in eight of these pairs the
case died (exact binomial probabilities: 0.037). The esti-
mated attributable mortality was 19.5% (95% CI 3.2–35.8),
and the estimated odds ratio was 2.7 (95% CI 1.02–7.10).
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Table 1
Results of matching of cases to control patients using four
major criteria
Proportion of cases
matched to
control patients
Criterion n/n %
Same primary diagnosis 35/36 97
Same duration of stay in ICU (±5 days) 31/36 86
Same APACHE II score (±5) 29/36 81
Same age (± 5 years) 27/36 75
APACHE, Acute Physiology and Chronic Health Evaluation; ICA,
intensive care unit.Primary diagnosis in the nine discordant case–control pairs
was septic shock in six pairs, acute pancreatitis in one pair,
undetermined shock in one pair and haemorrhagic shock
in one pair. Causes of mortalities included refractory
septic shock in eight cases (47%) and four control patients
(40%); multiple organ failure-related sepsis in five cases
(29%) and three control patients (30%); uncontrolled
bleeding in four cases (24%) and two control patients
(20%); and one undetermined shock in one contol (10%).
Sensitivity analyses were done to explore whether mor-
tality risk varies according to exposure. Thus, 17 cases
experienced a thrombocytopenia below 50×109
platelets/l for more than 3 days. Mortality rate was 47%,
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Table 2
Matching criteria and clinical characteristics of the study population
Cases Control patients 
Parameter (n = 36) (n = 36) P
Matching criteria
Primary diagnosis 0.99
Septic shock [n (%)] 12 (33) 12 (33)
Postoperative bleeding, gastrointestinal hemorrhage, trauma [n (%)] 14 (39) 13 (36)
Acute respiratory failure [n (%)] 3 (8) 3 (8)
Complication during post partum [n (%)] 2 (6) 2 (6)
Cardiac failure [n (%)] 1 (3) 2 (6)
Miscellaneous [n (%)]* 4 (11) 4 (11)
Duration of stay in ICU (days) 8.3±8.4 6.5±6.4 0.29
APACHE II score (points) 22.7±8.6 20.9±8.3 0.35
Age (years) 60.7±19.1 60.6±17.4 0.97
Characteristics
Sex (male/female) 20/16 22/14 0.63
Severity of underlying disease 0.81
Fatal or ultimately fatal [n (%)] 19 (53) 18 (50)
Nonfatal [n (%)] 17 (47) 18 (50)
Previous health status 0.80
No functional or moderate limitation [n (%)] 25 (69) 26 (72)
Serious limitation or bedridden or institutionalized [n (%)] 11 (31) 10 (28)
SAPS II score (points) 49.7±18.9 46.7±21.9 0.54
Expected mortality (%)† 46.0 39.1 –
ODIN model on admission –
Cardiac failure [n (%)] 22 (61) 21 (58)
Respiratory failure [n (%)] 30 (83) 30 (83)
Haematologic failure [n (%)] 20 (55) 13 (36)
Neurologic failure [n (%)] 6 (17) 10 (28)
Hepatic failure [n (%)] 1 (3) 2 (5)
Presence of infection [n (%)] 19 (53) 16 (44)
Total no. of organ system failure 2.8±1.2 2.9±1.2 0.60
*Miscellaneous included two cases of nosocomial pneumonia, one
case of acute pancreatitis, and one case of undetermined shock.
†Calculated from the equation proposed by Le Gall et al. [18].
APACHE, Acute Physiology and Chronic Health Evaluation; ODIN,
organ dysfunstion and/or infection; ICU, intensive care unit; SAP,
Simplified Acute Physiology Score.
Table 3
Crude mortality, attributable mortality, and odds ratio of death
due to severe thrombocytopenia in intensive care unit patients
Point estimate
Variable n/n % 95% CI
Crude mortality (cases) 17/36 47.2
Crude mortality (control patients) 10/36 27.8
Attributable mortality 7/36 19.4 3.2–35.8
Odds ratio 2.7 1.02–7.10
CI, confidence interval.versus 53 in patients without a prolonged thrombocy-
topenia (not significant). Likewise, among the 16 cases
transfused with platelets, eight died (50%) compared
with nine (45%) cases who were not transfused (not sig-
nificant). A last sensitivity analysis was done on the
timing variable. In 15 cases, thrombocytopenia occurred
more than 2 days after ICU admission. Mortality rate was
65% in these patients compared with 35% in cases in
whom thrombocytopenia occurred 2 days or less after
ICU admission (P=0.008).
Two time-point analyses of illness severity scores in the
nine discordant pairs showed that the APACHE II, SAPS
II and ODIN model scores were significantly higher for
cases than for control patients on the day of thrombo-
cytopenia (Table 4). Moreover, cases had comparable
values of severity of illness scores between day of admis-
sion and day of thrombocytopenia; this was contrary to the
situation with control patients, who had a statistically
significant decrease in severity of illness scores during the
same period (Table 4).
Blood product consumption
Thirty (83%) cases required transfusion of blood products,
versus 21 (58%) control patients (Table 5). Thirteen pairs
had discordant transfusion requirements, and in 11 of
these pairs the cases were transfused (paired c2 4.92,
P<0.04). The estimated attributable transfusion require-
ment was 25% (95% CI 5.4–44.6), and the estimated odds
ratio was 1.52 (95% CI 1.05–2.20).
Units of RBCs transfused were 8.0±7.0 (median 7.5)
versus 2.6±4.3 (median 1.5; P<0.0001), and units of fresh
frozen plasma transfused were 5.0±7.0 (median 1.0)
versus 1.0±2.0 (median 0; P=0.05) in cases and control
patients, respectively. Sixteen cases (44.4%) received
platelet transfusion (5.3±7.7 units of platelets transfused),
versus no control patients. In eight patients (one died),
platelet transfusions resulted in a rise of platelet count to
greater than 50×109/l, with a correction of thrombocyto-
penia a few days later. In eight patients (seven died), only
a transient rise of platelet count was noted and thrombocy-
topenia persisted during the entire ICU stay, despite
platelet transfusion. After onset of thrombocytopenia,
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Table 4
Comparison of illness severity scores between cases and control patients on the day of admission and on the day of onset of
thrombocytopenia in the nine discordant pairs
Score Cases (n = 9) Control patients (n = 9) P
APACHE II (median)
Day of admission 25.2±4.2 (25) 24.0±6.7 (26) NS
Day of thrombocytopenia 30.7±8.3 (47) 12.9±5.2 (11)* 0.04
SAPS II (median)
Day of admission 46.6±10.5 (47) 46.9±16.9 (40) NS
Day of thrombocytopenia 58±18.2 (51) 32.1±10.4 (31)* 0.04
ODIN model (median)
Day of admission 3.3±1.4 (4) 3.0±1.0 (3) NS
Day of thrombocytopenia 3.8±0.67 0.7±1 (0)* 0.008
Expected mortality (%)†
Day of admission 39.1 39.1 –
Day of thrombocytopenia 64.0 12.8 –
*P < 0.05 by Wilcoxon’s signed-rank test (score on day of admission
versus score on day of thrombocytopenia in control group).
†Calculated from the equation proposed by Le Gall et al. [18].
Table 5
Crude transfusion requirements, attributable transfusion
requirements, and odds ratio of transfusion requirements due
to severe thrombocytopenia in intensive care unit patients
Point estimate
Variable n/n % 95% CI
Crude transfusion requirements
Cases 30/36 83.0
Control patients 21/36 58.0
Attributable transfusion 9/36 25.0 5.4–44.6
requirements
Odds ratio 1.52 1.05–2.20
CI, confidence interval.4.4±7.2 units of RBCs and 2.5±5.4 units of fresh frozen
plasma were transfused. This represents about 50% of the
total transfusion requirements.
Discussion
The present results suggest that thrombocytopenia of less
than 50×109 platelets/l in ICU patients is associated with
increased mortality, with a relative risk of 2.7 (95%CI
1.02–7.10), and with excess blood product consumption,
with a relative risk of 1.52 (95%CI 1.05–2.20).
The incidence rate of thrombocytopenia reported in the
present study (12% surgical ICU patients) is in the range
reported in previous studies [1,3]. There are many expla-
nations for the thrombocytopenia observed in the context
of infection. DIC [23], immune mechanisms [23], and
haemophagocytic histiocytes [24,25] are the commonest
mechanisms of increased platelet destruction during bac-
terial infection. In critically ill surgical patients, blood loss
with subsequent volume replacement using crystalloids or
colloids, when sufficiently severe, can significantly
decrease the platelet count [26]. Likewise, a fall in
platelet count has been noted after blood transfusions, and
the incidence of thrombocytopenia has been specifically
reported to be directly proportional to the number of RBC
transfusions [2].
Patients with more severe underlying illness are more
likely to develop thrombocytopenia [1–3,5–7], and the
severity of underlying illness has an important impact on
the outcome of ICU patients with severe thrombocyto-
penia [1,3,5–7]. As previously suggested, mortality appears
to be proportional to the nadir platelet count [1,3,4]. Rela-
tively old studies [7,12,27] reported that thrombocytope-
nia was associated with an increased mortality rate in
septic patients. Recent studies using multivariate analysis
have reported conflicting results, however. Sprung et al
[5], in a large prospective study, identified thrombo-
cytopenia (<100×109 platelets/l) as an independent pre-
dictor of poor prognosis in septic patients, corresponding
to a relative risk of death of 1.66 (95%CI 1.06–2.60). In a
recent multicenter prospective study, Brun-Buisson et al
[13] also reported a relative risk of late mortality of 1.5
(95% CI 1.2–2.0) in severely ill septic thrombocytopenic
patients (platelet count <50×109/l). Another smaller study
[6] showed comparable results in septic patients. On the
other hand, Pittet et al [28] did not identify thrombo-
cytopenia as an independent predictor of mortality at the
onset of sepsis in ICU patients, like Brun-Buisson et al
[13] did for early mortality. Finally, when the entire cohort
of ICU patients was studied, thrombocytopenia was not
identified as a variable that was independently associated
with death in two studies [3,6]. These discrepencies may
be attributable to differences in the variables and
analytical methods used, and could also result from the
complex interactions noted in multivariate analysis.
Case–control studies require a considerably smaller
sample size than the corresponding longitudinal studies,
and is as effective as the cohort study as a basis for causal
inference [29]. Critical to the validity of this study is the
success in matching cases and control patients for impor-
tant confounding variables, especially the severity of
underlying illness. We used three variables that are
strongly correlated with outcome in patients admitted to
ICUs to match cases and control patients [17,18]: age, a
severity of disease scoring system (APACHE II), and spe-
cific diagnostic categories according to the one main
reason for admission. Matching was 84.3% successful for
288 possible variables. To verify the adequacy of matching
for severity of underlying illness and primary diagnosis
independently, we compared the cases and control
patients with respect to another seven potentially con-
founding variables. No statistically significant differences
in these indices were observed between cases and control
patients. It may be argued that we matched patients at the
time of admission. We realize that this does not reflect the
severity of illness at the time of thrombocytopenia, and
that matching on variables recorded at the time or just
before the diagnosis of thrombocytopenia may have
yielded different results. The reliability of systems such as
APACHE II, SAPS II and ODIN is not sufficiently
defined to study the daily probability of death, however.
Moreover, thrombocytopenia is linked to admission char-
acteristics and/or diagnosis, because nearly 60% of patients
with thrombocytopenia occurred during the first 2 days
after ICU admission.
We found that severe thrombocytopenia is associated with
increased mortality, mainly in septic patients, thereby con-
firming the results of previous cohort studies [5,6,13]. In
the ICU setting, however, thrombocytopenia is a
symptom that has been associated with several acute dis-
eases [1–3,23–26]. It is therefore difficult to distinguish
causes from consequences of severe thrombocytopenia
clearly in critically ill patients. For example, it is difficult
to state that bleeding not represent the results of thrombo-
cytopenia rather than the cause. Although matched
case–control studies are attractive because matching
assumes comparability for certain variables, the finding of
a higher mortality in cases compared with in control
patients only implies an association between mortality and
thrombocytopenia. Thus, the present analysis identified
an increased difference in severity of illness scores
between cases and control patients between the day of
admission and the day of thrombocytopenia. The finding
that illness severity decreased over time in control
patients, but remained constant in the cases, supports the
notion that severe thrombocytopenia probably largely
reflects the unfavourable course of the underlying disease
and possibly the aggravating role of thrombocytopenia
itself. Thrombocytopenia lasting for less than 3 days
confers a similar risk to that of thrombocytopenia for many
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failed to restore a normal platelet count, but normalization
of platelet count, when it occured, was associated with
better prognosis, as previously reported [3,24,27].
Patients who require intensive platelet support frequently
have complex medical problems, including DIC, clinical
bleeding and uncontrolled sepsis. Patients in this setting
receive multiple drugs and frequent blood product trans-
fusions. Patients with thrombocytopenia secondary to
sepsis often require platelet transfusions, although their
response is often suboptimal because of continued
platelet destruction, reflecting the persistance of the
underlying disease. Likewise, in patients receiving
massive transfusion, thrombocytopenia is due both to con-
sumption of platelets and to dilution by transfused blood
and colloid fluid resuscitation. These patients may also
have platelet function defects due to DIC, hypothermia
and ‘stunned’ recently transfused platelets. Patients may
remain midly thrombocytopenic for several days before
having a rebound thrombocytosis [30]. Of interest, the
mortality impact of thrombocytopenia occurred during the
first 2 days after ICU admission, which is quite different
from late-onset ICU-acquired thrombocytopenia. This
result is in agreement with a previous analysis [13] that
indicated that late mortality is essentially associated with
the characteristics of the underlying disease.
The mechanism of increased mortality directly related to
thrombocytopenia is difficult to assess, but several points
should be considered. First, the present results show that
severely thrombocytopenic patients required more blood
product transfusions. In addition to the possible volume
overload, higher postoperative infection rates have been
reported in patients who received blood transfusions [31].
Another study [32], however, did not confirm this relation-
ship. Second, platelets play key and multifactorial roles in
antimicrobial host defences [11]. For example, in the
absence of neutropenia, thrombocytopenia has been posi-
tively correlated with an increased incidence and severity
of pneumonia in elderly patients [33]. Third, cases had a
lower nadir haemoglobin value than control patients. Two
recent studies have [9,10] shown that patients with a car-
diovascular diagnosis and a high degree of acute illness
appear to be at increased risk of death from a moderate
degree of anaemia. Finally, severe thrombocytopenia is an
important risk factor for spontaneous intracerebral haem-
orrhage associated with a high mortality in critically ill
patients [34].
Conclusion
The present report shows that thrombocytopenia of less
than 50×109 platelets/l is associated with excess mortality
that is independent of the patient’s age and initial severity
of illness, and leads to excess blood product consumption,
thus imposing a significant economic burden. Thrombo-
cytopenia appears to be mostly a marker of severity of
underlying processes, rather than causally related to death.
Thus, the exact relationship between thrombocytopenia
and mortality has yet to be elucidated, especially in septic
patients. Further studies of the specific role of thrombocy-
topenia in shock and infections are necessary. Moreover,
the risks and benefits of the various strategies for the man-
agement of thrombocytopenic ICU patients should be re-
evaluated in a variety of clinical settings.
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